Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RETROSPECTIVE JAPANESE REAL WORLD STUDY OF METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB PLUS IPILIMUMAB (J-cardinal study)

Next Previous
X
Search
Trial Profile

RETROSPECTIVE JAPANESE REAL WORLD STUDY OF METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB PLUS IPILIMUMAB (J-cardinal study)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms J-cardinal study
  • Sponsors Bristol-Myers Squibb; Ono Pharmaceutical

    • Most Recent Events

    • 03 Nov 2022 Results of effectiveness of nivolumab plus ipilimumab combination therapy and of second-line therapy, using 2-year analysis, published in the Japanese Journal of Clinical Oncology
    • 01 Sep 2022 Status changed from active, no longer recruiting to completed.
    • 01 Dec 2021 Interim results were published in the Anticancer Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top